- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03910010
Brain Imaging Study on Biomarkers for Fibromyalgia
June 13, 2023 updated by: Nova Scotia Health Authority
Drugs used for managing Fibromyalgia pain have not proven to be effective and pain continues to cost Canadians $60 billion a year without truly helping those who suffer.
The study proposes to investigate the factors related to a person that can enhance or reduce the effectiveness of pain treatments in people suffering with Fibromyalgia pain.
Treatment response to painkillers in a person may be related to their brain, social, and psychological makeup.
The investigators aim to study these factors to identify and develop feasible and robust indicators based on a person's biological makeup (also called biomarkers).
These biomarkers will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.
These measures will offer new opportunities for improving treatment such as by tailoring treatment to meet the specific needs of each patient based on his/her biological and psychological makeup.
Towards the specific aim, data will first be collected in several experimental domains for studying treatment expectations (cognitive, psychosocial, brain-related).
These 'experimental' data will be compared between Fibromyalgia (FM) and healthy participants to yield new understanding of the factors that govern treatment response.
At the end of experimental data collection, the investigators will collect data in the 'clinical' domain.
Hence, at the end of the experimental sessions, a subset of FM participants will receive a mock drug (placebo disguised as an approved pain treatment) and another subset will provide pain ratings only and hence serve as a waiting list control for the placebo trial.
Data will be studied in steps to understand factors that mediate treatment outcomes and finally the investigators will use advanced computational tools used for big data analysis and aim to identify factors that can be used as biomarkers and precision medicine tools.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
35
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Javeria A Hashmi, PhD
- Phone Number: 902-473-4603
- Email: javeria.hashmi@dal.ca
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3h1V7
- Recruiting
- Nova Scotia Health Authority
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Chronic pain participant inclusion criteria:
- 18-75 years of age
- Right-handed
- Meet the classification criteria of chronic low back pain (having low back pain for more than 6 months).
- At least 4/10 clinical pain on the Brief Pain Inventory Scale on average during the two weeks prior to enrollment
- Comfortable completing (reading and writing) questionnaires and tasks with English language instructions
Healthy participant inclusion criteria:
- 18 - 75 years of age
- Right-handed
- Comfortable completing (reading and writing) questionnaires and tasks with English language instructions
Exclusion Criteria:
Chronic pain participant exclusion criteria:
- History of cardiac, respiratory, or nervous system disease that may interfere with participation in the study or cause heightened potential for adverse outcome. For example: asthma or claustrophobia
- Presence of any contraindications to MRI scanning. For example:
cardiac pacemaker, metal implants, fear of closed spaces, pregnancy
Healthy participant exclusion criteria:
- Acute or chronic pain
- History of cardiac, respiratory, or nervous system disease that, in the investigator's judgment and by asking the participant about their comfort level and ability, precludes participation in the study because of a heightened potential for adverse outcome. For example: asthma or claustrophobia
- Presence of any contraindications to MRI scanning. For example:
cardiac pacemaker, metal implants, fear of closed spaces, pregnancy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: placebos
Fibromyalgia participants will enter in an optional placebo trial.
This phase of the study will test the clinical usefulness of the biomarkers.
We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant.
Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain.
They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
|
Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain.
They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
|
No Intervention: Waitlist
Fibromyalgia participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar or on REDCap.
|
|
No Intervention: Healthy Controls
Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pain modulation- using an experimental task that tests a person's ability to form positive expectations.
Time Frame: 3 days after first visit
|
Brain imaging will be used to assess each participant's capacity to endogenously adjust pain perception with changes in expectations.
|
3 days after first visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2021
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
January 1, 2035
Study Registration Dates
First Submitted
April 8, 2019
First Submitted That Met QC Criteria
April 8, 2019
First Posted (Actual)
April 10, 2019
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 13, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5748
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Viking Therapeutics, Inc.Active, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States, Belgium, France, Mexico, Puerto Rico
-
Shengjing HospitalEnrolling by invitation
-
University of Maryland, BaltimoreStanford UniversityWithdrawnHeart Failure NYHA Class IV